Indrayani Biotech (BOM:526445) Piotroski F-Score: 3 (As of Jul. 04, 2026) — Near Median


BOM:526445 Indrayani Biotech Ltd BOM:526445
53 GF Score
Price ₹8.52
GF Value ₹40.86
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Indrayani Biotech Piotroski F-Score?

Indrayani Biotech BOM:526445 -4.05% 53 Piotroski F-Score is 3 as of Jul. 04, 2026, which is at its 10-year median of 3.00. GuruFocus rates BOM:526445 with a GF Score™ of 53/100 and a GF Value™ of ₹40.86 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,064 Business Services companies, Indrayani Biotech ranks worse than 85.06% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Indrayani Biotech has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Indrayani Biotech's Piotroski F-Score or its related term are showing as below:

BOM:526445' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 8
Current: 3

During the past 13 years, the highest Piotroski F-Score of Indrayani Biotech was 8. The lowest was 1. And the median was 3.

Indrayani Biotech  (BOM:526445) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Indrayani Biotech Piotroski F-Score Related Terms


Indrayani Biotech Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Indrayani Biotech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indrayani Biotech Piotroski F-Score Chart

Indrayani Biotech Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 8.00 7.00 3.00 3.00

Indrayani Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.00 0.00 0.00 0.00

BOM:526445 vs CTAS, CPRT, ULS: Piotroski F-Score Comparison

For the Specialty Business Services subindustry, Indrayani Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indrayani Biotech Piotroski F-Score vs Business Services Industry

For the Business Services industry and Industrials sector, Indrayani Biotech's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Indrayani Biotech's Piotroski F-Score falls into.


BOM:526445
53GF Score
Indrayani Biotech Ltd BOM:526445
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was ₹-61 Mil.
Cash Flow from Operations was ₹-67 Mil.
Revenue was ₹1,302 Mil.
Gross Profit was ₹475 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was (2340.016 + 2678.898) / 2 = ₹2509.457 Mil.
Total Assets at the begining of this year (Mar24) was ₹2,340 Mil.
Long-Term Debt & Capital Lease Obligation was ₹654 Mil.
Total Current Assets was ₹1,779 Mil.
Total Current Liabilities was ₹1,025 Mil.
Net Income was ₹104 Mil.

Revenue was ₹1,662 Mil.
Gross Profit was ₹691 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was (1559.625 + 2340.016) / 2 = ₹1949.8205 Mil.
Total Assets at the begining of last year (Mar23) was ₹1,560 Mil.
Long-Term Debt & Capital Lease Obligation was ₹707 Mil.
Total Current Assets was ₹1,450 Mil.
Total Current Liabilities was ₹871 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Indrayani Biotech's current Net Income (TTM) was -61. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Indrayani Biotech's current Cash Flow from Operations (TTM) was -67. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=-61.075/2340.016
=-0.02610025

ROA (Last Year)=Net Income/Total Assets (Mar23)
=104.224/1559.625
=0.06682632

Indrayani Biotech's return on assets of this year was -0.02610025. Indrayani Biotech's return on assets of last year was 0.06682632. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Indrayani Biotech's current Net Income (TTM) was -61. Indrayani Biotech's current Cash Flow from Operations (TTM) was -67. ==> -67 <= -61 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=654.152/2509.457
=0.26067472

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=706.635/1949.8205
=0.36241028

Indrayani Biotech's gearing of this year was 0.26067472. Indrayani Biotech's gearing of last year was 0.36241028. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=1779.351/1024.837
=1.7362283

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=1449.76/870.723
=1.66500713

Indrayani Biotech's current ratio of this year was 1.7362283. Indrayani Biotech's current ratio of last year was 1.66500713. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Indrayani Biotech's number of shares in issue this year was 45.536. Indrayani Biotech's number of shares in issue last year was 45.536. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=474.563/1302.284
=0.36440822

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=690.931/1662.256
=0.4156586

Indrayani Biotech's gross margin of this year was 0.36440822. Indrayani Biotech's gross margin of last year was 0.4156586. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=1302.284/2340.016
=0.55652782

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=1662.256/1559.625
=1.06580492

Indrayani Biotech's asset turnover of this year was 0.55652782. Indrayani Biotech's asset turnover of last year was 1.06580492. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+1+1+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Indrayani Biotech has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Indrayani Biotech (BOM:526445) has a Piotroski F-Score of 3 as of Jul. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Indrayani Biotech and its competitors. This is near median its historical median of 3.00. Over the past decade, Indrayani Biotech's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Indrayani Biotech ranks #905 out of 1064 companies in the Business Services industry, placing it in the top 85.1%.
Is Indrayani Biotech's Piotroski F-Score too high?
Indrayani Biotech's current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Business Services industry median Piotroski F-Score is 5.00. Indrayani Biotech's value of 3 is 40% below this industry median. Based on the distribution chart, Indrayani Biotech ranks #905 out of 1064 companies in the Business Services industry, which is in the bottom quartile relative to peers. Overall, Indrayani Biotech has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indrayani Biotech's Piotroski F-Score compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Indrayani Biotech ranks #905 out of 1064 companies for Piotroski F-Score. This places Indrayani Biotech in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Indrayani Biotech's value of 3 is 40% below this benchmark. Historically, Indrayani Biotech's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Indrayani Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Business Services company?
The median Piotroski F-Score among Business Services companies is 5.00, based on 1,064 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indrayani Biotech's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Indrayani Biotech and its competitors. For the Business Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indrayani Biotech's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indrayani Biotech stock overvalued right now?
Based on GuruFocus' analysis, Indrayani Biotech (BOM:526445) is currently considered Possible Value Trap. The stock's GF Value™ is ₹40.86, compared to a current price of ₹8.52 — trading 79.1% below its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 40% below the Business Services industry median of 5.00. Indrayani Biotech's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Indrayani Biotech (BOM:526445), the current Piotroski F-Score is 3 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indrayani Biotech (BOM:526445) Overvalued in 2026?

Based on GuruFocus' analysis, Indrayani Biotech stock appears to be undervalued. The current stock price of ₹8.52 is trading 79.1% below its estimated GF Value™ of ₹40.86. GuruFocus considers Indrayani Biotech to be Possible Value Trap.

Key valuation signals for BOM:526445:

  • Piotroski F-Score: 3 (near median its 10-year median of 3.00)
  • GF Value™: ₹40.86 vs. price of ₹8.52 (79.1% below fair value)
  • GF Score™: 53/100 with 7 warning signs
  • Industry Position: 40% below the Business Services median (#905 of 1064)

No single metric tells the full story. See the BOM:526445 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indrayani Biotech Business Description

Address Module No. 33, Block 1, 3rd Floor, SIDCO Electronic Complex, Thiru-vi-ka Industrial Estate, Guindy, Chennai, TN, IND, 600032
Indrayani Biotech Ltd operates in the Tri-segment i.e. Foods & Hospitality, Engineering and Healthcare divisions. The company generates its revenue from the sale of food, beverages, and other items; the Sale of Engineering products & Others. The majority of its revenue is generated from the sale of food, beverages, and other items.
53GF Score

Get the complete analysis for BOM:526445

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8.52
Price
₹40.86
GF Value